Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.97 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.59 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.50 |
| ▸ | PNMT | P11086 | 11/20 | 0.97 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487047 | 0.98 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL29941551 | 0.98 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL30471185 | 0.92 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL4709338 | 0.92 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL11325673 | 0.90 | PNMT (0.79) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL11765973 | 0.90 | PNMT (0.78) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL6955385 | 0.88 | PNMT (0.81) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL19712095 | 0.86 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL18022665 | 0.84 | PNMT (0.74) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL11475677 | 0.83 | PNMT (0.69) | PNMTADRA2AADRA2BADRA2CHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1956962-B | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS | 2014-08-20 | — | — | CN | disclosed |
| US-8586748-B2 | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| CN-1956962-A | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | CN | disclosed |
| US-7084154-B2 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA DRUG DISCLOVERY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| CN-1191249-C | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2005-03-02 | — | — | CN | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| CN-1205693-A | Quinoline and quinazoline compounds useful in therapy | PFIZER RES & DEV (IE) | 1999-01-20 | — | — | CN | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
| US-4242346-A | INHIBITION OF TRANSFERASE ENZYME NECESSARY IN BIOSYNTHESIS OF EPINEPHRINE | SMITHKLINE CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | ADRA2A 131/4885ADRA2B 200/4885ADRA2C 72/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | ADRA2A 277/4885ADRA2B 193/4885ADRA2C 116/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | ADRA2A 26/4885ADRA2B 189/4885ADRA2C 61/4885 |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | CCR10, CCR1, CCR4 | ADRA2A 93/4885ADRA2B 189/4885ADRA2C 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.